Clinical trials: NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Myocardial Infarction, STEMI
Breisgau PHENO-HEART MI
Coronary heart disease and its acute complication, myocardial infarction (MI), represent the leading causes of death in Europe and the United States.
- Conditions
- Myocardial Infarction, STEMI, NSTEMI
- Trial name
- NCT06166407
- Testing
- no intervention
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- University Hospital Freiburg
Ischemic Heart Disease, Stable Coronary Artery Disease
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)
- Conditions
- Ischemic Heart Disease, Stable Coronary Artery Disease, Stable Angina, Unstable Angina
- Trial name
- NCT03089450
- Testing
- CGBio stent, Biomatrix flex
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- CGBio Inc.